Radiopharmaceuticals in Cancer Disorders: Clinical and Pharmaceutical Perspectives
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".
Deadline for manuscript submissions: 31 January 2026 | Viewed by 18
Special Issue Editor
Interests: medicinal chemistry; biomarkers; radiopharmaceuticals; radiomics; anticancer activity; in vitro/in vivo
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Radiopharmaceuticals have emerged as powerful tools in both the diagnosis and treatment of cancer, offering distinct advantages through their ability to selectively target tumors at the molecular level. The expanding field of theranostics—referring to the coordinated use of diagnostic and therapeutic radiopharmaceuticals, whether in a single agent or as a matched pair of compounds—has underscored the clinical value of radiolabeled entities such as 177Lu-DOTATATE and 68Ga-PSMA in oncology. Clinicians benefit from improved imaging precision and targeted radiotherapy, while pharmaceutical scientists are essential to the development, formulation, and quality assurance of these agents to ensure safety, stability, and efficacy.
This Special Issue aims to foster interdisciplinary dialogue between clinical practice and pharmaceutical research. We hope that it will provide a platform to explore the design and synthesis of novel radiopharmaceuticals, pharmacokinetic considerations, fundamental regulatory principles relevant across jurisdictions, clinical trial outcomes, and the integration of radiopharmaceuticals into personalized cancer care.
Dr. Marta Rusek
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiopharmaceuticals
- cancer theranostics
- targeted radionuclide therapy
- molecular imaging
- pharmaceutical development
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
